{
    "nct_id": "NCT05650879",
    "official_title": "A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer",
    "inclusion_criteria": "Phase 1a Monotherapy Dose Escalation and Exploration:\n\n* Pathologically documented advanced stage solid tumor\n* Progressed following all standard treatment or not appropriate for standard treatment\n* HER2 mutation, HER2 amplification or HER2 positive based on local testing\n\nPhase 1b Monotherapy\n\n* Pathologically documented unresectable and/or metastatic non-squamous NSCLC\n* HER2 mutation identified by tissue (fresh or archival) or ctDNA. Local testing for up to 20 patients the remainder centrally confirmed.\n* Measurable disease\n* No known epidermal growth factor receptor (EGFR), ROS1, anaplastic lymphoma kinase (ALK), or BRAF V600E mutation\n* Progressed after receiving at least 1 prior systemic therapy including a platinum-based chemotherapy with or without immunotherapy, or not appropriate for standard treatment.\n* No prior HER2 tyrosine kinase inhibitor. Prior HER2 directed antibodies or anti-body drug conjugates are allowed\n* No limit on prior number of therapies\n\nPhase 1a Combination with T-DXd\n\n* Pathologically documented advanced stage NSCLC\n* Progressed after receiving at least 1 prior systemic therapy.\n* HER2 mutation based on local/historical testing of tissue or circulating tumor DNA\n* No known EGFR, ROS1, ALK, or BRAF V600E mutation\n* No prior T-DXd\n* No clinically severe pulmonary compromise\n* No limit on prior number of therapies\n\nPhase 1a Combination Breast Cancer\n\n* Documented HER2 positive (Immunohistochemical [IHC] 3+ or IHC2+/in situ hybridization (ISH+) breast cancer\n* Must have previously received trastuzumab, a taxane, and T-DXd (if available and appropriate) in the metastatic setting.\n* No limit on prior number of therapies\n* No prior T-DM1\n\nAll Phases\n\n* Eastern Cooperative Oncology Group performance status of 0-1\n* Left ventricular ejection fraction ≥ 50%\n* Platelet count ≥ 100 x 109/L\n* Hemoglobin ≥ 8.5 g/dL\n* Absolute neutrophil count ≥1.0 x 109/L\n* Total bilirubin < 1.5 times upper limit of normal range (ULN), except for patients with Gilbert's syndrome\n* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 3 times ULN. In the setting of liver metastases < 5 times ULN.\n* Creatinine clearance ≥ 60 mL/minute\n\nExclusion Criteria All Phases:\n\n* Severe cardiac arrhythmias, requiring treatment, symptomatic congestive heart failure, myocardial infarction within 28 days prior to first dose, or unstable angina.\n* Another active malignancy within 2 years except basal cell skin cancer and carcinoma in situ treated curatively\n* Active or chronic liver disease\n* Active infection requiring systemic therapy within 14 days before the first dose\n* Brain lesion requiring immediate local therapy\n* Leptomeningeal disease\n* Uncontrolled seizures\n* Corrected QT interval (QTc) of >470 milliseconds (ms) females or >450 ms for males by Fridericia (QTcF)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}